Cancer Family
Glandular Cell Neoplasm
CI-CAN-00000188Explore in graph →
Non-malignant2,825 active trials43 approved drugs426 evidence items
- NCIt
- C7132
Loading cancer entity…
Cancer Family
CI-CAN-00000188Explore in graph →
Clinical trials
10,213 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05516628 | Deep, Multi-omics Phenotyping to Predict Response, Resistance and Recurrence to Adjuvant Atezolizumab Plus Bevacizumab in Resected Hepatocellular Carcinoma(EMPHASIS) | recruiting | Phase 2 | 30 | National Cancer Centre, SingaporeOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT06008158 | Evaluation of a Once Per Day Regimen of Accelerated Partial Breast Irradiation for Improved Breast Appearance in Pts w/Low Risk, Hormone Responsive Brst Ca | active not recruiting | Phase 2 | 48 | City of Hope Medical CenterOTHER |
| 1 |
| Jun 29, 2026 |
| clinicaltrials |
| NCT06780787 | FOLFOX, Botensilimab, and Balstilimab for the Treatment of Localized Rectal Cancer Before Surgery | recruiting | Phase 2 | 26 | City of Hope Medical CenterOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07574489 | Whole Versus Partial Gland Boost During Prostate SBRT | not yet recruiting | Phase 2 / Phase 3 | 186 | University of NebraskaOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT06959641 | XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer | recruiting | Phase 2 | 33 | Jochen LorchOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT07042919 | Zanzalintinib in Second Line and Beyond for the Treatment of Advanced Liver Cancer | recruiting | Phase 1 / Phase 2 | 59 | Devalingam MahalingamOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07669220 | A Multicenter, Randomized Controlled Phase II Study of Short-Course Radiotherapy Followed by Sequential PD-1 Inhibitor and FOLFOX Chemotherapy Versus Long-Course Chemoradiotherapy for High-Risk Locally Advanced pMMR/MSS Lower Rectal Adenocarcinoma (STAR Trial)(STAR) | recruiting | Phase 2 | 76 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT02750358 | Feasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR (+) Triple Negative Breast Cancer | active not recruiting | Phase 2 | 50 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT05770531 | Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy | recruiting | Phase 2 | 160 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT06835972 | A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC) | recruiting | Phase 1 / Phase 2 | 43 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT07217990 | Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer(NoCUT-BC) | not yet recruiting | Phase 1 / Phase 2 | 84 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT07665684 | Samuraciclib in Combination With Gemcitabine/Nab-Paclitaxel in Patients With Metastatic Basal-Like Pancreatic Cancer(SONIC) | not yet recruiting | Phase 1 / Phase 2 | 67 | University Health Network, TorontoOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT04114136 | Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies | recruiting | Phase 2 | 72 | Dan ZandbergOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT04929392 | Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer | active not recruiting | Phase 2 | 3 | City of Hope Medical CenterOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT06038578 | A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer | recruiting | Phase 2 | 146 | Toray Industries, IncINDUSTRY | 3 | Jun 23, 2026 | clinicaltrials |
| NCT07432633 | [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications | recruiting | Phase 1 / Phase 2 | 71 | Blue Earth DiagnosticsINDUSTRY | 1 | Jun 23, 2026 | clinicaltrials |
| NCT07581314 | Oral Zn-Telomir Monotherapy in Patients With Advanced or Metastatic Triple-Negative Breast Cancer (TNBC) | not yet recruiting | Phase 1 / Phase 2 | 76 | Telomir Pharmaceuticals, Inc.INDUSTRY | 0 | Jun 23, 2026 | clinicaltrials |
| NCT03110978 | Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung Cancer | active not recruiting | Phase 2 | 140 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT04727307 | Neoadjuvant Atezo, Adjuvant Atezo + Beva Combined With RF Ablation of Small HCC: a Multicenter Randomized Phase II Trial(AB-LATE02) | active not recruiting | Phase 2 | 202 | University Hospital, MontpellierOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT07658872 | Perioperative Fruquintinib Combined With Sintilimab and SOX for Locally Advanced Gastric or GEJ Adenocarcinoma | not yet recruiting | Phase 2 | 120 | Sichuan UniversityOTHER | 0 | Jun 22, 2026 | clinicaltrials |
| NCT06381154 | Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer | active not recruiting | Phase 2 | 24 | Mayo ClinicOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07624487 | Aumolertinib Combined With Phased Chemotherapy for EGFR L858R Lung Adenocarcinoma | recruiting | Phase 2 | 50 | Taipei Medical University HospitalOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07635238 | A Study of Lower Dose Radiation Therapy for People With Prostate Cancer | recruiting | Phase 2 | 54 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07655661 | Mannatide Combined With CAPOX and Tislelizumab for Advanced Gastric Cancer. | not yet recruiting | Phase 2 | 52 | Ming LiuOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07657273 | Yttrium-90 Carbon Microsphere Radioembolization in Previously Treated Hepatocellular Carcinoma | not yet recruiting | Phase 2 | 20 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07658105 | Eparlitozoviril as Adjuvant Therapy for Resectable HCC With MVI(Ad-rHCC) | active not recruiting | Phase 2 | 60 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | active not recruiting | Phase 2 | 798 | National Cancer Institute (NCI)NIH | 2 | Jun 17, 2026 | clinicaltrials |
| NCT04837209 | Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer(NADiR) | active not recruiting | Phase 2 | 32 | Massachusetts General HospitalOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT07219238 | Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE) | recruiting | Phase 2 / Phase 3 | 175 | GE HealthcareINDUSTRY | 2 | Jun 17, 2026 | clinicaltrials |
| NCT07596290 | Yang et al. Anti-PD-1/CTLA-4 Dual Immunotherapy for LARC(RADICAL) | not yet recruiting | Phase 2 / Phase 3 | 342 | Beijing Friendship HospitalOTHER | 0 | Jun 17, 2026 | clinicaltrials |
| NCT07655024 | TAIC FOLFOX for Locally Advanced G/GEJA(TFLAG) | recruiting | Phase 2 | 31 | Guang'anmen Hospital of China Academy of Chinese Medical SciencesOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT01950351 | Hypofractionated Proton Beam Therapy for Localized Prostate Cancer | active not recruiting | Phase 2 | 241 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT06028022 | Reishi Mushroom Extract for Fatigue and/or Arthralgias/Myalgias in Patients With Breast Cancer on Aromatase Inhibitors | recruiting | Phase 2 | 80 | Mayo ClinicOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT06392295 | PSMA-Directed Para-Aortic Radiation Therapy for Oligorecurrent Prostate Cancer(OCEAN) | recruiting | Phase 2 | 34 | University of MiamiOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT06843434 | A Study of Botensilimab and Balstilimab for Rectal Adenocarcinoma | recruiting | Phase 2 | 40 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT07547553 | A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC | recruiting | Phase 1 / Phase 2 | 30 | Huahui HealthINDUSTRY | 1 | Jun 16, 2026 | clinicaltrials |
| NCT06447103 | An Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the Detection of Recurrent Clear Cell Renal Cell Cancer After Surgery Comparing Carbonic Anhydrase IX (CAIX) PET CT to Conventional PET CT for Post-Op Staging in Kidney Cancer | recruiting | Phase 2 | 91 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT07647263 | Trastuzumab Rezetecan Neoadjuvant Therapy in THP-Insensitive HER2-Positive Early Breast Cancer | recruiting | Phase 2 | 124 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT00715442 | Pre-Surgical Sutent in Renal Cell Carcinoma (RCC) | active not recruiting | Phase 2 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT04616183 | LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer | active not recruiting | Phase 1 / Phase 2 | 46 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT04729322 | Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders | active not recruiting | Phase 2 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT05639972 | E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers | recruiting | Phase 1 / Phase 2 | 15 | Christian HinrichsOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT05686226 | E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers | recruiting | Phase 2 | 20 | Christian HinrichsOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT05982496 | 18F FES-PET/MRI for Tailoring Treatment of Luminal A and Lobular Breast Cancer(FESTA) | recruiting | Phase 2 | 119 | Università Vita-Salute San RaffaeleOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT06051695 | A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression(EVEREST-2) | recruiting | Phase 1 / Phase 2 | 474 | A2 Biotherapeutics Inc.INDUSTRY | 1 | Jun 12, 2026 | clinicaltrials |
| NCT06494150 | Nab-Sirolimus and Endocrine Therapy in Recurrent Low Grade Serous Ovarian Cancer (NARETO) | active not recruiting | Phase 2 | 37 | University of OklahomaOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT07644208 | PD-1/IL-2 Bispecific Antibody as Neoadjuvant Therapy for Early Recurrent Hepatocellular Carcinoma After Curative Hepatectomy | not yet recruiting | Phase 2 | 30 | Shanghai Zhongshan HospitalOTHER | 0 | Jun 12, 2026 | clinicaltrials |
| NCT02971748 | Pembrolizumab in Treating Patients With Hormone Receptor Positive, Localized Inflammatory Breast Cancer Who Are Receiving Hormone Therapy and Did Not Achieve a Pathological Complete Response to Chemotherapy | active not recruiting | Phase 2 | 36 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT03936478 | Real-Time MRI-Guided 3-Fraction Accelerated Partial Breast Irradiation in Early Breast Cancer(MAPBI) | recruiting | Phase 2 | 30 | University of Wisconsin, MadisonOTHER | 1 | Jun 11, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Jun 29, 2026source: clinicaltrials